Published in Neuropsychopharmacology on January 11, 2012
Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol (2014) 1.14
The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep (2012) 1.04
The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep (2012) 0.99
The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci (2013) 0.92
Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep (2014) 0.91
Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology (2013) 0.89
Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front Neurosci (2013) 0.88
Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? Trends Neurosci (2016) 0.87
Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci (2013) 0.86
Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Front Neurosci (2013) 0.82
The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors. Psychopharmacology (Berl) (2014) 0.81
Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Front Behav Neurosci (2014) 0.80
Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans. Psychopharmacology (Berl) (2014) 0.79
Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. BMC Neurosci (2014) 0.79
Evaluation of potential PET imaging probes for the orexin 2 receptors. Nucl Med Biol (2013) 0.79
Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Sci Rep (2016) 0.78
Enhanced slow-wave EEG activity and thermoregulatory impairment following the inhibition of the lateral hypothalamus in the rat. PLoS One (2014) 0.77
Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys. Sleep (2016) 0.75
Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard. Psychiatry Clin Neurosci (2001) 36.50
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell (1999) 9.84
Sleep state switching. Neuron (2010) 4.94
Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci (1995) 4.02
Sleep deprivation and vigilant attention. Ann N Y Acad Sci (2008) 3.60
Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci (2005) 3.53
Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A (1999) 3.42
Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med (2007) 3.25
Afferents to the orexin neurons of the rat brain. J Comp Neurol (2006) 2.57
GABA(A) receptor diversity and pharmacology. Cell Tissue Res (2006) 2.19
Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci (2001) 1.81
The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci (2000) 1.72
Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci (2003) 1.64
Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol (2011) 1.53
Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology (2001) 1.40
The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. Sleep Med Rev (2010) 1.33
Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci (2011) 1.29
Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Sleep (1999) 1.29
Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci (2011) 1.23
The association between insomnia severity and healthcare and productivity costs in a health plan sample. Sleep (2011) 1.16
Effect of zolpidem on sleep and sleep EEG spectra in healthy young men. Psychopharmacology (Berl) (1991) 1.14
Abnormal sleep/wake dynamics in orexin knockout mice. Sleep (2010) 1.10
Sleep, sleep disorders and hypocretin (orexin). Sleep Med (2004) 1.08
Alternating vigilance states: new insights regarding neuronal networks and mechanisms. Eur J Neurosci (2009) 1.07
Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol (2009) 1.07
Role of GABAA receptors in the physiology and pharmacology of sleep. Eur J Neurosci (2009) 1.05
Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res (2001) 1.02
Orexin (hypocretin)/dynorphin neurons control GABAergic inputs to tuberomammillary neurons. Eur J Neurosci (2004) 1.02
Convergence of circadian and sleep regulatory mechanisms on hypocretin-1. Neuroscience (2004) 1.01
Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. Hum Psychopharmacol (2001) 0.95
Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol (2011) 0.95
A potent non-monoaminergic paradoxical sleep inhibitory system: a reverse microdialysis and single-unit recording study. Eur J Neurosci (2006) 0.93
Sex differences and the effect of gaboxadol and zolpidem on EEG power spectra in NREM and REM sleep. J Psychopharmacol (2009) 0.88
Orexins/hypocretins and aminergic systems. Acta Physiol (Oxf) (2009) 0.85
Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon. Br J Clin Pharmacol (2002) 0.85
Antagonizing the effects of experimentally induced sleep disturbance in healthy volunteers by lormetazepam and zolpidem. J Clin Psychopharmacol (1995) 0.85
Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs (2009) 0.83
Next-day residual effects of gaboxadol and flurazepam administered at bedtime: a randomized double-blind study in healthy elderly subjects. Hum Psychopharmacol (2009) 0.79
Enhanced slow wave sleep and improved sleep maintenance after gaboxadol administration during seven nights of exposure to a traffic noise model of transient insomnia. J Psychopharmacol (2011) 0.79
Comparison of the effects of zolpidem and triazolam on nocturnal sleep and sleep latency in the morning: a cross-over study in healthy young volunteers. Prog Neuropsychopharmacol Biol Psychiatry (2000) 0.78
Distribution of REM latencies and other sleep phenomena in depression as explained by a single ultradian rhythm disturbance. Sleep (1984) 0.77
Transgenic mice with a reduced core body temperature have an increased life span. Science (2006) 3.37
PER3 polymorphism predicts sleep structure and waking performance. Curr Biol (2007) 2.93
Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry (2011) 2.21
Daytime light exposure dynamically enhances brain responses. Curr Biol (2006) 2.17
Interindividual variation in sleep duration and its association with sleep debt in young adults. Sleep (2005) 2.07
Getting through to circadian oscillators: why use constant routines? J Biol Rhythms (2002) 2.02
Sex difference in the near-24-hour intrinsic period of the human circadian timing system. Proc Natl Acad Sci U S A (2011) 1.97
Age-related reduction in the maximal capacity for sleep--implications for insomnia. Curr Biol (2008) 1.97
Effects of insufficient sleep on circadian rhythmicity and expression amplitude of the human blood transcriptome. Proc Natl Acad Sci U S A (2013) 1.94
Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep (2006) 1.80
Uncovering residual effects of chronic sleep loss on human performance. Sci Transl Med (2010) 1.66
Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. Psychopharmacology (Berl) (2005) 1.61
Low-dose repeated caffeine administration for circadian-phase-dependent performance degradation during extended wakefulness. Sleep (2004) 1.54
Light as a modulator of cognitive brain function. Trends Cogn Sci (2009) 1.47
Peak of circadian melatonin rhythm occurs later within the sleep of older subjects. Am J Physiol Endocrinol Metab (2002) 1.46
Early morning executive functioning during sleep deprivation is compromised by a PERIOD3 polymorphism. Sleep (2008) 1.43
Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci (2011) 1.35
Effects of partial and acute total sleep deprivation on performance across cognitive domains, individuals and circadian phase. PLoS One (2012) 1.35
Absolute quantification of cerebral blood flow with magnetic resonance, reproducibility of the method, and comparison with H2(15)O positron emission tomography. J Cereb Blood Flow Metab (2002) 1.34
Daily and seasonal variation in the spectral composition of light exposure in humans. Chronobiol Int (2009) 1.33
Blue-enriched white light in the workplace improves self-reported alertness, performance and sleep quality. Scand J Work Environ Health (2008) 1.32
Mistimed sleep disrupts circadian regulation of the human transcriptome. Proc Natl Acad Sci U S A (2014) 1.30
Brain responses to violet, blue, and green monochromatic light exposures in humans: prominent role of blue light and the brainstem. PLoS One (2007) 1.28
The spectral composition of evening light and individual differences in the suppression of melatonin and delay of sleep in humans. J Pineal Res (2011) 1.28
Gut memories: towards a cognitive neurobiology of irritable bowel syndrome. Neurosci Biobehav Rev (2011) 1.25
Effects of three weeks of mild sleep restriction implemented in the home environment on multiple metabolic and endocrine markers in healthy young men. Metabolism (2012) 1.20
Functional magnetic resonance imaging-assessed brain responses during an executive task depend on interaction of sleep homeostasis, circadian phase, and PER3 genotype. J Neurosci (2009) 1.20
Nonvisual responses to light exposure in the human brain during the circadian night. Curr Biol (2004) 1.18
Age-related change in the association between a polymorphism in the PER3 gene and preferred timing of sleep and waking activities. J Sleep Res (2007) 1.18
Uncoupling protein 2 protects dopaminergic neurons from acute 1,2,3,6-methyl-phenyl-tetrahydropyridine toxicity. J Neurochem (2005) 1.18
Daytime exposure to bright light, as compared to dim light, decreases sleepiness and improves psychomotor vigilance performance. Sleep (2003) 1.16
Inter-individual differences in habitual sleep timing and entrained phase of endogenous circadian rhythms of BMAL1, PER2 and PER3 mRNA in human leukocytes. Sleep (2008) 1.16
Sleep, diurnal preference, health, and psychological well-being: a prospective single-allelic-variation study. Chronobiol Int (2012) 1.13
Age-related reduction in daytime sleep propensity and nocturnal slow wave sleep. Sleep (2010) 1.12
Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal. Psychopharmacology (Berl) (2002) 1.11
Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol (2004) 1.09
Older people awaken more frequently but fall back asleep at the same rate as younger people. Sleep (2004) 1.09
Human circadian melatonin rhythm phase delay during a fixed sleep-wake schedule interspersed with nights of sleep deprivation. J Pineal Res (2003) 1.04
The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep (2012) 1.04
Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. Psychopharmacology (Berl) (2008) 1.03
Sleep function: current questions and new approaches. Eur J Neurosci (2009) 1.02
Robust circadian rhythm in heart rate and its variability: influence of exogenous melatonin and photoperiod. J Sleep Res (2007) 1.01
The suitability of actigraphy, diary data, and urinary melatonin profiles for quantitative assessment of sleep disturbances in schizophrenia: a case report. Chronobiol Int (2006) 1.00
Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones. J Clin Endocrinol Metab (2003) 1.00
Plasma melatonin rhythms in young and older humans during sleep, sleep deprivation, and wake. Sleep (2007) 1.00
Effects of light on cognitive brain responses depend on circadian phase and sleep homeostasis. J Biol Rhythms (2011) 0.98
Assessment of circadian rhythms in humans: comparison of real-time fibroblast reporter imaging with plasma melatonin. FASEB J (2012) 0.97
PER3 polymorphism and cardiac autonomic control: effects of sleep debt and circadian phase. Am J Physiol Heart Circ Physiol (2008) 0.96
Alertness, mood and performance rhythm disturbances associated with circadian sleep disorders in the blind. J Sleep Res (2008) 0.96
Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol (2011) 0.95
Circadian period and the timing of melatonin onset in men and women: predictors of sleep during the weekend and in the laboratory. J Sleep Res (2012) 0.93
Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol (2011) 0.92
Effects of sleep inertia after daytime naps vary with executive load and time of day. Behav Neurosci (2011) 0.92
Manipulation of adenosine kinase affects sleep regulation in mice. J Neurosci (2010) 0.91
Expression, synaptic localization, and developmental regulation of Ack1/Pyk1, a cytoplasmic tyrosine kinase highly expressed in the developing and adult brain. J Comp Neurol (2005) 0.91
Survival analysis indicates that age-related decline in sleep continuity occurs exclusively during NREM sleep. Neurobiol Aging (2012) 0.91
Altered sleep and behavioral activity phenotypes in PER3-deficient mice. Am J Physiol Regul Integr Comp Physiol (2011) 0.90
Morning sleep inertia in alertness and performance: effect of cognitive domain and white light conditions. PLoS One (2013) 0.89
Injection of neuropeptide W into paraventricular nucleus of hypothalamus increases food intake. Am J Physiol Regul Integr Comp Physiol (2005) 0.89
Interindividual differences in circadian rhythmicity and sleep homeostasis in older people: effect of a PER3 polymorphism. Neurobiol Aging (2011) 0.87
Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia. Sleep (2013) 0.85
Anger-congruent behaviour transfers across driving situations. Cogn Emot (2011) 0.85
Characterization of a 7% carbon dioxide (CO2) inhalation paradigm to evoke anxiety symptoms in healthy subjects. J Psychopharmacol (2005) 0.84
Exploiting human and mouse transcriptomic data: Identification of circadian genes and pathways influencing health. Bioessays (2015) 0.83
A method to assess the dissipation of the [corrected] residual effects of [corrected] hypnotics: eszopiclone versus zopiclone. J Clin Psychopharmacol (2012) 0.83
Correlation and predictive performances of saliva and plasma nicotine concentration on tobacco withdrawal-induced craving. Br J Clin Pharmacol (2002) 0.82
Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: Part 1--pseudoequilibrium interval and quantification methods. J Nucl Med (2006) 0.82
Time to wake-up: sleep problems and daytime sleepiness in long-term stroke survivors. Brain Inj (2008) 0.81
Sleep of aging women and men: back to basics. Sleep (2006) 0.81
EEG power spectra and auditory P300 during free smoking and enforced smoking abstinence. Pharmacol Biochem Behav (2004) 0.81
Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep. J Psychopharmacol (2011) 0.80
A new EEG biomarker of neurobehavioural impairment and sleepiness in sleep apnea patients and controls during extended wakefulness. Clin Neurophysiol (2013) 0.80
Sleep- and circadian-dependent modulation of REM density. J Sleep Res (2002) 0.80
Why do we sleep so late? J Sleep Res (2013) 0.79
EEG power spectra response to a 4-h phase advance and gaboxadol treatment in 822 men and women. J Clin Sleep Med (2011) 0.79
The relation between poor sleep, impulsivity and aggression in forensic psychiatric patients. Physiol Behav (2013) 0.79
Slow wave sleep in patients with respiratory failure. Sleep Med (2011) 0.79
Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers. Psychopharmacology (Berl) (2011) 0.79
Sensitive to sleep loss or not: neurons, working memory, insomnia and the heart. J Sleep Res (2013) 0.79
Nocturia is associated with loss of deep sleep independently from sleep apnea. Neurourol Urodyn (2015) 0.79
Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo. Nucl Med Biol (2006) 0.77
Out of synch with society: an update on delayed sleep phase disorder. Curr Opin Pulm Med (2014) 0.77
Sleep and health: beyond sleep duration and sleepiness? J Sleep Res (2012) 0.76
Phenotyping sleep. J Sleep Res (2011) 0.75
Falling asleep at the wheel across Europe. J Sleep Res (2015) 0.75
Risk-taking and other effects of sleep loss on brain function and behaviour. J Sleep Res (2011) 0.75
Napping: when sleep is bad for you? J Sleep Res (2015) 0.75
Subjective sleepiness: an undervalued early sign of insufficient sleep? J Sleep Res (2014) 0.75
Sleep credit and debit: grey matter and emotional intelligence in the balance? J Sleep Res (2013) 0.75
Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. Clin Pharmacokinet (2003) 0.75
Sleep and metabolism: you sleep what you eat? J Sleep Res (2014) 0.75
Sleep spindles, mobile phones, lucid dreaming and sleep in Parkinson's disease and autism spectrum disorders. J Sleep Res (2012) 0.75